# PHL Treatment in Pancreatic Cancer

> **NCT05365893** · EARLY_PHASE1 · RECRUITING · sponsor: **Fox Chase Cancer Center** · enrollment: 20 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **COMBINATION_PRODUCT:** Paricalcitol, Hydroxychloroquine, Losartan
- **OTHER:** Neoadjuvant therapy and surgery only (Control)

## Key facts

- **NCT ID:** NCT05365893
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-20
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05365893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05365893, "PHL Treatment in Pancreatic Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05365893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*